Simulations Plus (NASDAQ:SLP) Issues FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.07-$1.20 for the period, compared to the consensus EPS estimate of $1.01. The company issued revenue guidance of $90-$93 million, compared to the consensus revenue estimate of $90.71 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Analysts Set New Price Targets

SLP has been the subject of several recent research reports. StockNews.com downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. William Blair restated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, November 6th. BTIG Research decreased their price target on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Finally, Stephens initiated coverage on Simulations Plus in a research note on Friday, November 15th. They set an “overweight” rating and a $39.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Simulations Plus currently has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Simulations Plus Trading Up 4.4 %

NASDAQ SLP traded up $1.29 during trading on Tuesday, hitting $30.39. The company had a trading volume of 492,972 shares, compared to its average volume of 303,448. The company’s fifty day moving average is $29.78 and its 200-day moving average is $34.16. The company has a market cap of $610.38 million, a price-to-earnings ratio of 62.02 and a beta of 0.80. Simulations Plus has a one year low of $27.07 and a one year high of $51.22.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The business had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. During the same period last year, the business posted $0.18 earnings per share. Simulations Plus’s quarterly revenue was up 19.9% compared to the same quarter last year. As a group, equities analysts anticipate that Simulations Plus will post 1.1 EPS for the current year.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $31.76, for a total transaction of $635,200.00. Following the completion of the transaction, the director now owns 3,442,584 shares of the company’s stock, valued at approximately $109,336,467.84. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 19.40% of the stock is owned by corporate insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.